Novo Nordisk v. Sun Pharma: Ozempic Semaglutide Patent Dispute Settled After 957 Days
Novo Nordisk A/S and Novo Nordisk Inc. filed suit against Sun Pharmaceutical Industries in Delaware District Court, asserting two patents covering Ozempic (semaglutide) subcutaneous injection formulations. After 957 days of litigation, both parties reached a negotiated settlement, with the case subsequently consolidated.
Novo Nordisk defends Ozempic formulation patents against Sun Pharma ANDA challenge
Novo Nordisk A/S and its U.S. affiliate Novo Nordisk Inc. filed this infringement action on 4 March 2022 in the District of Delaware against Sun Pharmaceutical Industries, Inc., asserting two patents — US10335462B2 and US9132239B2 — covering subcutaneous semaglutide injection formulations sold under the Ozempic brand. The specific product at issue was Ozempic in 2 mg/1.5 ml and 4 mg/3 ml concentrations, both at 1.34 mg/ml.
The case closed on 16 October 2024 following a negotiated settlement, with the docket noting the matter as consolidated. The settlement agreement sets out agreed terms and conditions between the parties but its specific commercial provisions — including any launch date, royalty arrangement, or licence grant — remain confidential and are not disclosed in the public record. Case consolidation suggests this action was joined with related Ozempic patent proceedings, consistent with multi-wave ANDA litigation strategy.
The 957-day duration is consistent with pharmaceutical patent disputes that proceed through substantive motion practice before resolving pre-trial, suggesting the parties engaged meaningfully in claim construction and discovery before reaching agreement. What drove the settlement — whether claim vulnerability, commercial timing, or litigation economics — cannot be determined from the public record. The consolidation basis of termination further suggests Novo Nordisk was managing coordinated parallel proceedings against multiple generic challengers simultaneously.
Filing to Case Consolidated in 957 days
957 days — above median for ANDA pharma patent disputes in Delaware
Negotiated settlement: what the resolution means for both parties
Settlement ends litigation — no merits ruling on patent validity
The parties entered a private settlement agreement resolving all claims in this action. Because the case settled, no court issued a ruling on whether the asserted claims of US10335462B2 or US9132239B2 are valid, infringed, or enforceable. This is legally significant: the patents survive unchallenged by any public adjudication, and Sun made no formal admission of infringement.
No validity ruling issuedNovo Nordisk preserves patent enforceability with no adverse ruling
For Novo Nordisk, settlement without an adverse judgment keeps both asserted patents intact and enforceable. Novo Nordisk retains the ability to assert US10335462B2 and US9132239B2 against other generic challengers. The confidential settlement terms may include a controlled entry date for Sun, which would represent a commercially negotiated outcome protecting the Ozempic franchise while avoiding litigation risk.
Patents remain enforceableSun Pharma avoids adverse judgment — settlement terms control market access
Sun Pharmaceutical secured resolution without a public finding of infringement. However, the practical outcome depends entirely on undisclosed settlement terms. Any agreed launch date or licence restrictions would govern when Sun can enter the semaglutide injectable market. Without a court ruling invalidating the patents, Sun’s path to market remains subject to whatever constraints the settlement imposes.
Launch terms undisclosedOzempic patent fortress reinforced — generic competition timeline uncertain
The settlement, combined with case consolidation, suggests Novo Nordisk is managing a coordinated litigation programme across multiple semaglutide challengers. Each settlement on undisclosed terms adds uncertainty to generic entry timelines, which is commercially significant given Ozempic’s blockbuster revenue profile. Competitors and payers tracking generic semaglutide availability should note that no patent has been adjudicated invalid in this or related proceedings.
Generic entry timeline opaqueFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Individual | Global pharmaceutical innovator — holder of US10335462B2 and US9132239B2 covering Ozempic (semaglutide)Search in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk, Inc. | Company | Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Sun Pharmaceutical Industries, Inc. — generic and specialty pharmaceutical manufacturer seeking Ozempic market entrySearch in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Defendant counsel | Christopher B. Ferenc | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher W. West | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Richards Layton & Finger PA | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text records a mutual agreement to settle on negotiated terms memorialised in a formal settlement agreement. The phrasing — ‘agreed to terms and conditions representing a negotiated settlement’ — confirms a bilateral resolution without any court determination on the merits. No finding of infringement, validity, or invalidity was made. The practical legal effect is that both asserted patents, US10335462B2 and US9132239B2, remain in their pre-litigation enforceability posture, and Novo Nordisk retains full rights to assert them in future proceedings.
US10335462B2 & US9132239B2 — Semaglutide subcutaneous injectable formulations
US10335462B2 (application US15/656042) and US9132239B2 (application US13/124995) both relate to pharmaceutical formulation technology covering semaglutide, the active GLP-1 receptor agonist ingredient in Ozempic. The patents protect specific compositional and formulation parameters — including concentration, excipient selection, and injectable presentation — that define the Ozempic subcutaneous product at 1.34 mg/ml. These are product and formulation patents sitting atop Novo Nordisk’s broader semaglutide IP estate.
For the pharmaceutical sector, these formulation patents are strategically critical because they extend effective exclusivity beyond any compound patent expiry. GLP-1 injectable formulations require precise stability, delivery, and concentration engineering, making design-around difficult without compromising product performance. Any generic or biosimilar developer targeting the semaglutide injectable market — including prefilled pen presentations — must assess whether their formulation falls within the claim scope of these patents. The commercial stakes are exceptionally high given Ozempic’s multi-billion dollar global revenue.
Should your semaglutide formulation programme run an FTO against US10335462B2?
Any pharmaceutical developer, CDMO, or generic manufacturer working on semaglutide subcutaneous injectables — including biosimilar, follow-on, or reformulated GLP-1 products — should conduct a freedom-to-operate analysis against US10335462B2 and US9132239B2 before committing to a formulation strategy. The product at issue, Ozempic at 1.34 mg/ml, is the reference listed drug; ANDA filers or 505(b)(2) applicants referencing Ozempic are directly exposed to these patents and should expect enforcement.
PatSnap Eureka’s FTO Search Agent can map your formulation parameters against the claim language of US10335462B2 and US9132239B2, identify prior art that may support invalidity arguments, and surface related Novo Nordisk semaglutide filings that could expand the enforcement perimeter. For R&D and regulatory teams operating in the GLP-1 space, early-stage FTO work informed by Eureka’s patent landscape analysis can materially reduce downstream litigation risk.
Run a freedom-to-operate analysis on US10335462B2 to assess your product’s exposure
Run FTO in Eureka →Similar semaglutide and GLP-1 ANDA patent cases in Delaware
Cases involving GLP-1 receptor agonist formulation patents litigated in Delaware District Court under the Hatch-Waxman framework, including parallel Ozempic and semaglutide proceedings.
What this case signals for the GLP-1 pharmaceutical IP landscape
Novo Nordisk’s coordinated ANDA litigation over Ozempic formulation patents sets a high bar for generic semaglutide entry and signals active portfolio enforcement.
Formulation patents remain the primary Ozempic defence layer
US10335462B2 and US9132239B2 cover specific semaglutide subcutaneous formulation parameters. Novo Nordisk’s willingness to litigate — and settle — rather than concede suggests these claims are sufficiently robust to deter generic entry without an IPR or trial loss. Companies developing GLP-1 injectables should map their formulations carefully against these claim boundaries.
Consolidated proceedings signal a multi-defendant enforcement programme
The ‘Case Consolidated’ basis of termination is consistent with Novo Nordisk running parallel ANDA actions against several generic filers simultaneously. This is a well-established originator strategy: coordinated suits create settlement pressure and extend the effective exclusivity window. Monitor related Delaware dockets for comparable Ozempic proceedings.
A/S v Sun — key questions answered
Novo Nordisk asserted two patents: US10335462B2 (application US15/656042) and US9132239B2 (application US13/124995), both covering semaglutide subcutaneous injectable formulations. The specific product at issue was Ozempic subcutaneous solution at 2 mg/1.5 ml and 4 mg/3 ml (both 1.34 mg/ml).
The case was resolved through a negotiated settlement agreement. The parties agreed to terms and conditions that resolved the infringement action. The specific commercial terms of the settlement are confidential and not disclosed in the public record. The case was subsequently noted as consolidated on 16 October 2024, consistent with coordinated multi-defendant ANDA litigation management.
No. Because the case settled before trial, no court issued any ruling on whether the asserted patents — US10335462B2 or US9132239B2 — are valid, invalid, infringed, or not infringed. Both patents remain in their pre-litigation enforceability posture and Novo Nordisk retains all rights to enforce them against other parties.
A ‘Case Consolidated’ termination basis typically indicates the case was merged with one or more related proceedings, likely other ANDA patent actions involving Ozempic formulations brought by Novo Nordisk against different generic challengers. This is consistent with Novo Nordisk running a coordinated multi-defendant enforcement strategy in Delaware District Court. The underlying settlement was reached before consolidation finalised the docket.
The settlement on undisclosed terms means the public record does not reveal when, if ever, Sun Pharmaceutical may launch a generic or competitive semaglutide injectable. Confidential settlement terms in ANDA cases frequently include an agreed authorised generic launch date or licence window. Without disclosure, competitors and payers tracking generic Ozempic availability cannot determine the effective exclusivity timeline from this proceeding alone.
PatSnap Eureka searches patents and litigation data to answer instantly.